180 related articles for article (PubMed ID: 38053285)
1. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease.
Shukla AK; Misra S
J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):25-29. PubMed ID: 38053285
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
Song T; Wang Y; Silverglate BD; Grossberg GT
Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
[TBL] [Abstract][Full Text] [Related]
3. Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials.
Rashad A; Rasool A; Shaheryar M; Sarfraz A; Sarfraz Z; Robles-Velasco K; Cherrez-Ojeda I
Healthcare (Basel); 2022 Dec; 11(1):. PubMed ID: 36611492
[TBL] [Abstract][Full Text] [Related]
4. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
[TBL] [Abstract][Full Text] [Related]
5. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
[TBL] [Abstract][Full Text] [Related]
6. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
[TBL] [Abstract][Full Text] [Related]
7. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
8. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
10. Still grasping at straws: donanemab in Alzheimer's disease.
Doggrell SA
Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295
[TBL] [Abstract][Full Text] [Related]
11. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
Lian Y; Jia YJ; Wong J; Zhou XF; Song W; Guo J; Masters CL; Wang YJ
Mol Psychiatry; 2024 Feb; 29(2):297-305. PubMed ID: 38001337
[TBL] [Abstract][Full Text] [Related]
12. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y; Gu J; Yu M; Chi Y; Ma Y
CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
[TBL] [Abstract][Full Text] [Related]
14. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Høilund-Carlsen PF; Alavi A; Barrio JR; Castellani RJ; Costa T; Herrup K; Kepp KP; Neve RL; Perry G; Revheim ME; Robakis NK; Sensi SL; Vissel B
Ageing Res Rev; 2024 Jun; ():102348. PubMed ID: 38830549
[TBL] [Abstract][Full Text] [Related]
15. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.
Söderberg L; Johannesson M; Gkanatsiou E; Nygren P; Fritz N; Zachrisson O; Rachalski A; Svensson AS; Button E; Dentoni G; Osswald G; Lannfelt L; Möller C
Sci Rep; 2024 May; 14(1):10868. PubMed ID: 38740836
[TBL] [Abstract][Full Text] [Related]
17. Profiling lecanemab as a treatment option for Alzheimer's disease.
Schiller ER; Silverglate BD; Grossberg GT
Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
[TBL] [Abstract][Full Text] [Related]
18. Updates on pharmacological treatment for Alzheimer's disease.
Tipton PW
Neurol Neurochir Pol; 2024; 58(2):150-160. PubMed ID: 37606550
[TBL] [Abstract][Full Text] [Related]
19. Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.
Espay AJ; Herrup K; Imbimbo BP; Kepp KP; Daly T
J Alzheimers Dis; 2024; 99(3):877-881. PubMed ID: 38701151
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects.
Loeffler DA
J Alzheimers Dis Rep; 2023; 7(1):873-899. PubMed ID: 37662616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
